Management of Severe Hypertriglyceridemia

Introduction to Guidelines

• The American Diabetes Association recommends aggressive optimization of diabetes control as the primary driver of severe hypertriglyceridemia, which can reduce triglycerides by 20-70% independent of lipid medications 1
• Uncontrolled diabetes mellitus is often the primary cause of severe hypertriglyceridemia, and optimizing glucose control can dramatically reduce triglycerides more effectively than additional lipid medications in many cases 1, 2

Assessing and Managing Fenofibrate Dosing

• The American College of Cardiology recommends verifying that fenofibrate dosing is appropriate for renal function, as inadequate dosing may explain the lack of triglyceride control 1
• If renal function is impaired (eGFR 30-59 mL/min/1.73 m²), fenofibrate should be initiated at 54 mg daily and not exceed this dose 1
• Fenofibrate is contraindicated if eGFR <30 mL/min/1.73 m² 1

Dietary Interventions

• The American Heart Association recommends restricting total dietary fat to 20-25% of total daily calories for triglycerides in the 500-999 mg/dL range, and completely eliminating all added sugars 1
• Completely eliminating all added sugars can reduce hepatic triglyceride production 1, 2
• Abstaining completely from all alcohol consumption can reduce triglycerides by 5-10% and prevent hypertriglyceridemic pancreatitis 1, 2

Prescription Omega-3 Fatty Acids

• The American College of Cardiology recommends adding icosapent ethyl 2g twice daily if triglycerides remain >200 mg/dL after 3 months of optimized diabetes control, maximized fenofibrate dosing, and lifestyle modifications 1
• Prescription omega-3 fatty acids (icosapent ethyl 2-4g daily) can provide an additional 20-50% triglyceride reduction when added to fenofibrate 1

Statin Therapy

• The American Diabetes Association recommends reassessing LDL-C and considering adding or optimizing statin therapy if LDL-C is elevated or cardiovascular risk is high once triglycerides are reduced below 500 mg/dL 1
• Statins provide an additional 10-30% dose-dependent triglyceride reduction 3, 1
• Target LDL-C goal is <100 mg/dL for diabetic patients (or <70 mg/dL for very high-risk patients) 3, 1

Monitoring and Treatment Goals

• The primary goal is to reduce triglycerides to <500 mg/dL to eliminate pancreatitis risk 1
• The secondary goal is to further reduce to <200 mg/dL (ideally <150 mg/dL) to reduce cardiovascular risk 1
• The tertiary goal is Non-HDL-C <130 mg/dL (calculated as total cholesterol minus HDL-C) 3, 1
• Target HgA1C <7% for patients with diabetes to help manage cardiovascular risk factors including triglycerides 1